-
1
-
-
33846018408
-
Is angiogenesis an organizing principle in biology and medicine?
-
Folkman, J. Is angiogenesis an organizing principle in biology and medicine? J. Pediatr. Surg. 42, 1-11 (2007).
-
(2007)
J. Pediatr. Surg.
, vol.42
, pp. 1-11
-
-
Folkman, J.1
-
2
-
-
0036780251
-
Clinical translation of angiogenesis inhibitors
-
Kerbel, R. & Folkman, J. Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer 2, 727-739 (2002).
-
(2002)
Nat. Rev. Cancer
, vol.2
, pp. 727-739
-
-
Kerbel, R.1
Folkman, J.2
-
3
-
-
74049088133
-
-
Bukowski, R. M, Yasothan, U. & Kirkpatrick, P. Pazopanib. Nat. Rev. Drug Discov. 9, 17-18 (2010).
-
(2010)
Pazopanib. Nat. Rev. Drug Discov.
, vol.9
, pp. 17-18
-
-
Bukowski, R.M.1
Yasothan, U.2
Kirkpatrick, P.3
-
4
-
-
47949089077
-
VEGF-targeted therapy: Mechanisms of anti-tumour activity
-
Ellis, L. M. & Hicklin, D. J. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat. Rev. Cancer 8, 579-591 (2008).
-
(2008)
Nat. Rev. Cancer
, vol.8
, pp. 579-591
-
-
Ellis, L.M.1
Hicklin, D.J.2
-
5
-
-
56749174211
-
FLT1 and its ligands VEGFB and PlGF: Drug targets for anti-angiogenic therapy?
-
Fischer, C., Mazzone, M., Jonckx, B. & Carmeliet, P. FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Nat. Rev. Cancer 8, 942-956 (2008).
-
(2008)
Nat. Rev. Cancer
, vol.8
, pp. 942-956
-
-
Fischer, C.1
Mazzone, M.2
Jonckx, B.3
Carmeliet, P.4
-
6
-
-
67349129399
-
Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies
-
Rapisarda, A. & Melillo, G. Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies. Drug Resist. Updat. 12, 74-80 (2009).
-
(2009)
Drug Resist. Updat.
, vol.12
, pp. 74-80
-
-
Rapisarda, A.1
Melillo, G.2
-
7
-
-
74849127957
-
Antiangiogenic agents and HIF-1 inhibitors meet at the crossroads
-
Rapisarda, A., Shoemaker, R. H. & Melillo, G. Antiangiogenic agents and HIF-1 inhibitors meet at the crossroads. Cell Cycle 8, 4040-4043 (2009).
-
(2009)
Cell Cycle
, vol.8
, pp. 4040-4043
-
-
Rapisarda, A.1
Shoemaker, R.H.2
Melillo, G.3
-
8
-
-
35548982639
-
Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels
-
Fischer, C. et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor- resistant tumors without affecting healthy vessels. Cell 131, 463-475 (2007).
-
(2007)
Cell
, vol.131
, pp. 463-475
-
-
Fischer, C.1
-
9
-
-
0031038068
-
Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor β-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis
-
Relf, M. et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor β-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res. 57, 963-969 (1997).
-
(1997)
Cancer Res.
, vol.57
, pp. 963-969
-
-
Relf, M.1
-
10
-
-
33846149645
-
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients
-
Batchelor, T. T. et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11, 83-95 (2007).
-
(2007)
Cancer Cell
, vol.11
, pp. 83-95
-
-
Batchelor, T.T.1
-
11
-
-
33749005405
-
Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors
-
Shaked, Y. et al., Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 313, 1785-1787 (2006).
-
(2006)
Science
, vol.313
, pp. 1785-1787
-
-
Shaked, Y.1
-
12
-
-
19944422751
-
Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoietin-1, and matrix metalloproteinases
-
Winkler, F. et al., Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6, 553-563 (2004).
-
(2004)
Cancer Cell
, vol.6
, pp. 553-563
-
-
Winkler, F.1
-
13
-
-
60649087564
-
Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis
-
Ebos, J. M. et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15, 232-239 (2009).
-
(2009)
Cancer Cell
, vol.15
, pp. 232-239
-
-
Ebos, J.M.1
-
14
-
-
60649116273
-
Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: Impact on local control and patient survival
-
Narayana, A. et al. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J. Neurosurg. 110, 173-180 (2009).
-
(2009)
J. Neurosurg.
, vol.110
, pp. 173-180
-
-
Narayana, A.1
-
15
-
-
41649112610
-
Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence
-
Norden, A. D. et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70, 779-787 (2008).
-
(2008)
Neurology
, vol.70
, pp. 779-787
-
-
Norden, A.D.1
-
16
-
-
60649106195
-
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis
-
Pàez-Ribes, M. et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15, 220 (2009).
-
(2009)
Cancer Cell
, vol.15
, pp. 220
-
-
Pàez-Ribes, M.1
-
17
-
-
79959944026
-
Antiangiogenic therapy, hypoxia, and metastasis: Risky liaisons, or not?
-
De Bock, K., Mazzone, M. & Carmeliet, P. Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not? Nat. Rev. Clin. Oncol. 8, 393-404 (2011).
-
(2011)
Nat. Rev. Clin. Oncol.
, vol.8
, pp. 393-404
-
-
De Bock, K.1
Mazzone, M.2
Carmeliet, P.3
-
18
-
-
34547820876
-
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells
-
Shojaei, F. et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat. Biotechnol. 25, 911-920 (2007).
-
(2007)
Nat. Biotechnol.
, vol.25
, pp. 911-920
-
-
Shojaei, F.1
-
20
-
-
50149109090
-
Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib
-
Padera, T. P. et al. Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib. Mol. Cancer Ther. 7, 2272-2279 (2008).
-
(2008)
Mol. Cancer Ther.
, vol.7
, pp. 2272-2279
-
-
Padera, T.P.1
-
21
-
-
58149521991
-
Differential effects of the vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 on tumor angiogenesis and tumor lymphangiogenesis
-
Schomber, T. et al. Differential effects of the vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 on tumor angiogenesis and tumor lymphangiogenesis. Mol. Cancer Ther. 8, 55-63 (2009).
-
(2009)
Mol. Cancer Ther.
, vol.8
, pp. 55-63
-
-
Schomber, T.1
-
22
-
-
0032053823
-
The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy
-
Brown, J. M. & Giaccia, A. J. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res. 58, 1408-1416 (1998).
-
(1998)
Cancer Res.
, vol.58
, pp. 1408-1416
-
-
Brown, J.M.1
Giaccia, A.J.2
-
23
-
-
50149097983
-
Hypoxia, HIF-1 and glucose metabolism in the solid tumour
-
Denko, N. C. Hypoxia, HIF-1 and glucose metabolism in the solid tumour. Nat. Rev. Cancer 8, 705-713 (2008).
-
(2008)
Nat. Rev. Cancer
, vol.8
, pp. 705-713
-
-
Denko, N.C.1
-
24
-
-
33745303045
-
Hypoxia signalling in cancer and approaches to enforce tumour regression
-
Pouysségur, J., Dayan, F. & Mazure, N. M. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441, 437-443 (2006).
-
(2006)
Nature
, vol.441
, pp. 437-443
-
-
Pouysségur, J.1
Dayan, F.2
Mazure, N.M.3
-
25
-
-
77957746194
-
Metabolic microenvironment of tumor cells: A key factor in malignant progression
-
Vaupel, P. Metabolic microenvironment of tumor cells: a key factor in malignant progression. Exp. Oncol. 32, 125-127 (2010).
-
(2010)
Exp. Oncol.
, vol.32
, pp. 125-127
-
-
Vaupel, P.1
-
26
-
-
0036359548
-
Hypoxia\a key regulatory factor in tumour growth
-
Harris, A. L. Hypoxia\a key regulatory factor in tumour growth. Nat. Rev. Cancer 2, 38-47 (2002).
-
(2002)
Nat. Rev. Cancer
, vol.2
, pp. 38-47
-
-
Harris, A.L.1
-
27
-
-
78649364332
-
Hypoxia-inducible factors and the response to hypoxic stress
-
Majmundar, A. J., Wong, W. J. & Simon, M. C. Hypoxia-inducible factors and the response to hypoxic stress. Mol. Cell 40, 294-309 (2010).
-
(2010)
Mol. Cell
, vol.40
, pp. 294-309
-
-
Majmundar, A.J.1
Wong, W.J.2
Simon, M.C.3
-
28
-
-
77951162650
-
Hypoxia-inducible factors in stem cells and cancer
-
Mazumdar, J., Dondeti, V. & Simon, M. C. Hypoxia-inducible factors in stem cells and cancer. J. Cell Mol. Med. 13, 4319-4328 (2009).
-
(2009)
J. Cell Mol. Med.
, vol.13
, pp. 4319-4328
-
-
Mazumdar, J.1
Dondeti, V.2
Simon, M.C.3
-
29
-
-
0030025773
-
Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
-
Graeber, T. G. et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379, 88-91 (1996).
-
(1996)
Nature
, vol.379
, pp. 88-91
-
-
Graeber, T.G.1
-
30
-
-
12144287046
-
Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and-independent mechanisms and contributes to drug resistance
-
Erler, J. T. et al. Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and-independent mechanisms and contributes to drug resistance. Mol. Cell Biol. 24, 2875-2889 (2004).
-
(2004)
Mol. Cell Biol.
, vol.24
, pp. 2875-2889
-
-
Erler, J.T.1
-
31
-
-
74949118681
-
The unfolded protein response protects human tumor cells during hypoxia through regulation of the autophagy genes MAP1LC3B and ATG5
-
Rouschop, K. M. et al. The unfolded protein response protects human tumor cells during hypoxia through regulation of the autophagy genes MAP1LC3B and ATG5. J. Clin. Invest 120, 127-141 (2010).
-
(2010)
J. Clin. Invest
, vol.120
, pp. 127-141
-
-
Rouschop, K.M.1
-
32
-
-
84866601479
-
Regulation of metabolism by hypoxia-inducible factor 1
-
Semenza, G. L. Regulation of metabolism by hypoxia-inducible factor 1. Cold Spring Harb. Symp. Quant. Biol. http://dx.doi.org/10.1101/sqb.2011.76. 010678.
-
Cold Spring Harb. Symp. Quant. Biol
-
-
Semenza, G.L.1
-
33
-
-
33745138232
-
Regulation of angiogenesis by hypoxia-inducible factor 1
-
Hirota, K. & Semenza, G. L. Regulation of angiogenesis by hypoxia-inducible factor 1. Crit. Rev. Oncol. Hematol. 59, 15-26 (2006).
-
(2006)
Crit. Rev. Oncol. Hematol.
, vol.59
, pp. 15-26
-
-
Hirota, K.1
Semenza, G.L.2
-
34
-
-
33845707705
-
VEGF and PlGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor neovascularization
-
Li, B. et al. VEGF and PlGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor neovascularization. FASEB J. 20, 1495-1497 (2006).
-
(2006)
FASEB J.
, vol.20
, pp. 1495-1497
-
-
Li, B.1
-
35
-
-
79954579633
-
EMT: A new vision of hypoxia promoting cancer progression
-
Jiang, J., Tang, Y. L. & Liang, X. H. EMT: a new vision of hypoxia promoting cancer progression. Cancer Biol. Ther. 11, 714-723 (2011).
-
(2011)
Cancer Biol. Ther.
, vol.11
, pp. 714-723
-
-
Jiang, J.1
Tang, Y.L.2
Liang, X.H.3
-
36
-
-
78149260621
-
Hypoxic tumors and their effect on immune cells and cancer therapy
-
Yotnda, P., Wu, D. & Swanson, A. M. Hypoxic tumors and their effect on immune cells and cancer therapy. Methods Mol. Biol. 651, 1-29 (2010).
-
(2010)
Methods Mol. Biol.
, vol.651
, pp. 1-29
-
-
Yotnda, P.1
Wu, D.2
Swanson, A.M.3
-
37
-
-
39749114978
-
Hypoxia and metabolism. Hypoxia DNA repair and genetic instability
-
Bristow, R. G. & Hill, R. P. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat. Rev. Cancer 8, 180-192 (2008).
-
(2008)
Nat. Rev. Cancer
, vol.8
, pp. 180-192
-
-
Bristow, R.G.1
Hill, R.P.2
-
38
-
-
24144493814
-
Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing
-
Guzy, R. D. et al. Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing. Cell Metab. 1, 401-408 (2005).
-
(2005)
Cell Metab.
, vol.1
, pp. 401-408
-
-
Guzy, R.D.1
-
39
-
-
76349095132
-
Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics
-
Semenza, G. L. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 29, 625-634 (2010).
-
(2010)
Oncogene
, vol.29
, pp. 625-634
-
-
Semenza, G.L.1
-
40
-
-
84863496502
-
-
(ed. Siemann D. W.) (John Wiley & Sons, Oxford
-
Rapisarda, A. & Melillo, G. in Tumor Microenvironment (ed. Siemann, D. W.) pp. 377-400 (John Wiley & Sons, Oxford, 2011).
-
(2011)
Tumor Microenvironment
, pp. 377-400
-
-
Rapisarda, A.1
Melillo, G.2
-
41
-
-
72849115544
-
Development of HIF-1 inhibitors for cancer therapy
-
Onnis, B., Rapisarda, A. & Melillo, G. Development of HIF-1 inhibitors for cancer therapy. J. Cell Mol. Med. 13, 2780-2786 (2009).
-
(2009)
J. Cell Mol. Med.
, vol.13
, pp. 2780-2786
-
-
Onnis, B.1
Rapisarda, A.2
Melillo, G.3
-
42
-
-
79957534572
-
Targeting hypoxia in cancer therapy
-
Wilson, W. R. & Hay, M. P. Targeting hypoxia in cancer therapy. Nat. Rev. Cancer 11, 393-410 (2011).
-
(2011)
Nat. Rev. Cancer
, vol.11
, pp. 393-410
-
-
Wilson, W.R.1
Hay, M.P.2
-
43
-
-
23444460271
-
Antiangiogenic therapy for cancer: Current and emerging concepts
-
Jain, R. K. Antiangiogenic therapy for cancer: current and emerging concepts. Oncology (Williston Park) 19 (4 Suppl. 3), 7-16 (2005).
-
(2005)
Oncology (Williston Park)
, vol.19
, Issue.4 SUPPL. 3
, pp. 7-16
-
-
Jain, R.K.1
-
44
-
-
0037478437
-
Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene
-
Pennacchietti, S. et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3, 347-361 (2003).
-
(2003)
Cancer Cell
, vol.3
, pp. 347-361
-
-
Pennacchietti, S.1
-
45
-
-
47949099628
-
Modes of resistance to anti-angiogenic therapy
-
Bergers, G. & Hanahan, D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 8, 592-603 (2008).
-
(2008)
Nat. Rev. Cancer
, vol.8
, pp. 592-603
-
-
Bergers, G.1
Hanahan, D.2
-
46
-
-
26644471951
-
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors
-
Casanovas, O., Hicklin, D. J., Bergers, G. & Hanahan, D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8, 299-309 (2005).
-
(2005)
Cancer Cell
, vol.8
, pp. 299-309
-
-
Casanovas, O.1
Hicklin, D.J.2
Bergers, G.3
Hanahan, D.4
-
47
-
-
33645735004
-
Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia
-
Franco, M. et al. Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia. Cancer Res. 66, 3639-3648 (2006).
-
(2006)
Cancer Res.
, vol.66
, pp. 3639-3648
-
-
Franco, M.1
-
48
-
-
79952740612
-
Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma
-
Keunen, O. et al. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc. Natl Acad. Sci. USA 108, 3749-3754 (2011).
-
(2011)
Proc. Natl Acad. Sci. USA
, vol.108
, pp. 3749-3754
-
-
Keunen, O.1
-
49
-
-
79959925745
-
Non-invasive monitoring of hypoxia-inducible factor activation by optical imaging during antiangiogenic treatment in a xenograft model of ovarian carcinoma
-
Martinez-Poveda, B. et al. Non-invasive monitoring of hypoxia-inducible factor activation by optical imaging during antiangiogenic treatment in a xenograft model of ovarian carcinoma. Int. J. Oncol. 39, 543-552 (2011).
-
(2011)
Int. J. Oncol.
, vol.39
, pp. 543-552
-
-
Martinez-Poveda, B.1
-
50
-
-
80053474763
-
Bevacizumab has differential and dose-dependent effects on glioma blood vessels and tumor cells
-
von Baumgarten, L. et al. Bevacizumab has differential and dose-dependent effects on glioma blood vessels and tumor cells. Clin. Cancer Res. 17, 6192-6205 (2011).
-
(2011)
Clin. Cancer Res.
, vol.17
, pp. 6192-6205
-
-
Von Baumgarten, L.1
-
51
-
-
84857407549
-
Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia
-
Conley, S. J. et al. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia Proc. Natl Acad. Sci. USA 109, 2784-2789 (2012).
-
(2012)
Proc. Natl Acad. Sci. USA
, vol.109
, pp. 2784-2789
-
-
Conley, S.J.1
-
52
-
-
84860800431
-
11C-labeled docetaxel in patients with non-small cell lung cancer (NSCLC): Implications for scheduling of antiangiogenic agents [abstract]
-
11C-labeled docetaxel in patients with non-small cell lung cancer (NSCLC): Implications for scheduling of antiangiogenic agents [abstract]. J. Clin. Oncol. 29 (Suppl.) a3059 (2011).
-
(2011)
J. Clin. Oncol.
, vol.29
, Issue.SUPPL.
-
-
Smit, E.F.1
-
53
-
-
80051544936
-
Antiangiogenic therapy for primary liver cancer: Correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response
-
Yopp, A. C. et al. Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response. Ann. Surg. Oncol. 18, 2192-2199 (2011).
-
(2011)
Ann. Surg. Oncol.
, vol.18
, pp. 2192-2199
-
-
Yopp, A.C.1
-
54
-
-
4043184065
-
Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1
-
Ceradini, D. J. et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat. Med. 10, 858-864 (2004).
-
(2004)
Nat. Med.
, vol.10
, pp. 858-864
-
-
Ceradini, D.J.1
-
55
-
-
43249095919
-
Tumor angiogenesis
-
Kerbel, R. S. Tumor angiogenesis. N. Engl. J. Med. 358, 2039-2049 (2008).
-
(2008)
N. Engl. J. Med.
, vol.358
, pp. 2039-2049
-
-
Kerbel, R.S.1
-
56
-
-
57849100048
-
Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche
-
Erler, J. T. et al. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 15, 35-44 (2009).
-
(2009)
Cancer Cell
, vol.15
, pp. 35-44
-
-
Erler, J.T.1
-
57
-
-
40949147521
-
Hypoxia-inducible factor-1 target genes as indicators of tumor vessel response to vascular endothelial growth factor inhibition
-
Dang, D. T. et al. Hypoxia-inducible factor-1 target genes as indicators of tumor vessel response to vascular endothelial growth factor inhibition. Cancer Res. 68, 1872-1880 (2008).
-
(2008)
Cancer Res.
, vol.68
, pp. 1872-1880
-
-
Dang, D.T.1
-
58
-
-
33750286135
-
The multifaceted circulating endothelial cell in cancer: Towards marker and target identification
-
Bertolini, F., Shaked, Y., Mancuso, P. & Kerbel, R. S. The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat. Rev. Cancer 6, 835-845 (2006).
-
(2006)
Nat. Rev. Cancer
, vol.6
, pp. 835-845
-
-
Bertolini, F.1
Shaked, Y.2
Mancuso, P.3
Kerbel, R.S.4
-
59
-
-
33749362031
-
Inhibiting hypoxia-inducible factor 1 for cancer therapy
-
Melillo, G. Inhibiting hypoxia-inducible factor 1 for cancer therapy. Mol. Cancer Res. 4, 601-605 (2006).
-
(2006)
Mol. Cancer Res.
, vol.4
, pp. 601-605
-
-
Melillo, G.1
-
60
-
-
77953935500
-
Tumour hypoxia induces a metabolic shift causing acidosis: A common feature in cancer
-
Chiche, J., Brahimi-Horn, M. C. & Pouysségur, J. Tumour hypoxia induces a metabolic shift causing acidosis: a common feature in cancer. J. Cell Mol. Med. 14, 771-794 (2010).
-
(2010)
J. Cell Mol. Med.
, vol.14
, pp. 771-794
-
-
Chiche, J.1
Brahimi-Horn, M.C.2
Pouysségur, J.3
-
61
-
-
54549089738
-
Hypoxia signalling through mTOR and the unfolded protein response in cancer
-
Wouters, B. G. & Koritzinsky, M. Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat. Rev. Cancer 8, 851-864 (2008).
-
(2008)
Nat. Rev. Cancer
, vol.8
, pp. 851-864
-
-
Wouters, B.G.1
Koritzinsky, M.2
-
62
-
-
68349135032
-
Regulation of autophagy through multiple independent hypoxic signaling pathways
-
Rouschop, K. M. & Wouters, B. G. Regulation of autophagy through multiple independent hypoxic signaling pathways. Curr. Mol. Med. 9, 417-424 (2009).
-
(2009)
Curr. Mol. Med.
, vol.9
, pp. 417-424
-
-
Rouschop, K.M.1
Wouters, B.G.2
-
63
-
-
78650333871
-
Targeting hypoxic cells through the DNA damage response
-
Olcina, M., Lecane, P. S. & Hammond, E. M. Targeting hypoxic cells through the DNA damage response. Clin. Cancer Res. 16, 5624-5629 (2010).
-
(2010)
Clin. Cancer Res.
, vol.16
, pp. 5624-5629
-
-
Olcina, M.1
Lecane, P.S.2
Hammond, E.M.3
-
64
-
-
0017256549
-
Increased cell killing by metronidazole and nitrofurazone of hypoxic compared to aerobic mammalian cells
-
Mohindra, J. K. & Rauth, A. M. Increased cell killing by metronidazole and nitrofurazone of hypoxic compared to aerobic mammalian cells. Cancer Res. 36, 930-936 (1976).
-
(1976)
Cancer Res.
, vol.36
, pp. 930-936
-
-
Mohindra, J.K.1
Rauth, A.M.2
-
65
-
-
39149094633
-
Homologous recombination is the principal pathway for the repair of DNA damage induced by tirapazamine in mammalian cells
-
Evans, J. W. et al. Homologous recombination is the principal pathway for the repair of DNA damage induced by tirapazamine in mammalian cells. Cancer Res. 68, 257-265 (2008).
-
(2008)
Cancer Res.
, vol.68
, pp. 257-265
-
-
Evans, J.W.1
-
66
-
-
77958060317
-
Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors
-
Hicks, K. O. et al. Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors. Clin. Cancer Res. 16, 4946-4957 (2010).
-
(2010)
Clin. Cancer Res.
, vol.16
, pp. 4946-4957
-
-
Hicks, K.O.1
-
67
-
-
0037119415
-
Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 α-degradative pathway
-
Isaacs, J. S. et al. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 α-degradative pathway. J. Biol. Chem. 277, 29936-29944 (2002).
-
(2002)
J. Biol. Chem.
, vol.277
, pp. 29936-29944
-
-
Isaacs, J.S.1
-
68
-
-
1242271198
-
Topoisomerase Imediated inhibition of hypoxia-inducible factor 1: Mechanism and therapeutic implications
-
Rapisarda, A. et al. Topoisomerase Imediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res. 64, 1475-1482 (2004).
-
(2004)
Cancer Res.
, vol.64
, pp. 1475-1482
-
-
Rapisarda, A.1
-
69
-
-
80052691602
-
Potent and sustained inhibition of HIF-1α and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects
-
Sapra, P. et al. Potent and sustained inhibition of HIF-1α and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects. Angiogenesis 14, 245-253 (2011).
-
(2011)
Angiogenesis
, vol.14
, pp. 245-253
-
-
Sapra, P.1
-
70
-
-
38349092288
-
Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1α
-
M. Y. Koh. et al. Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1α. Mol. Cancer Ther. 7, 90-100 (2008).
-
(2008)
Mol. Cancer Ther.
, vol.7
, pp. 90-100
-
-
Koh, M.Y.1
-
71
-
-
33744829237
-
CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1α/VEGF signaling
-
Wan, X., Shen, N., Mendoza, A., Khanna, C. & Helman, L. J. CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1α/VEGF signaling. Neoplasia 8, 394-401 (2006).
-
(2006)
Neoplasia
, vol.8
, pp. 394-401
-
-
Wan, X.1
Shen, N.2
Mendoza, A.3
Khanna, C.4
Helman, L.J.5
-
72
-
-
33745242315
-
Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus
-
Del Bufalo, D. et al. Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus. Cancer Res. 66, 5549-5554 (2006).
-
(2006)
Cancer Res.
, vol.66
, pp. 5549-5554
-
-
Del Bufalo, D.1
-
73
-
-
56249131779
-
A RNA antagonist of hypoxia-inducible factor-1α, EZN-2968, inhibits tumor cell growth
-
Greenberger, L. M. et al. A RNA antagonist of hypoxia-inducible factor-1α, EZN-2968, inhibits tumor cell growth. Mol. Cancer Ther. 7, 3598-3608 (2008).
-
(2008)
Mol. Cancer Ther.
, vol.7
, pp. 3598-3608
-
-
Greenberger, L.M.1
-
74
-
-
77956286559
-
Aminoflavone, a ligand of the aryl hydrocarbon receptor, inhibits HIF-1α expression in an AhR-independent fashion
-
Terzuoli, E. et al. Aminoflavone, a ligand of the aryl hydrocarbon receptor, inhibits HIF-1α expression in an AhR-independent fashion. Cancer Res. 70, 6837-6848 (2010).
-
(2010)
Cancer Res.
, vol.70
, pp. 6837-6848
-
-
Terzuoli, E.1
-
75
-
-
60549092506
-
Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells
-
Lee, K. et al. Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells. Proc. Natl Acad. Sci. USA 106, 2353-2358 (2009).
-
(2009)
Proc. Natl Acad. Sci. USA
, vol.106
, pp. 2353-2358
-
-
Lee, K.1
-
76
-
-
33748194210
-
Development of a cell-based reporter assay for screening of inhibitors of hypoxia-inducible factor 2-induced gene expression
-
Woldemichael, G. M. et al. Development of a cell-based reporter assay for screening of inhibitors of hypoxia-inducible factor 2-induced gene expression. J. Biomol. Screen. 11, 678-689 (2006).
-
(2006)
J. Biomol. Screen.
, vol.11
, pp. 678-689
-
-
Woldemichael, G.M.1
-
77
-
-
79960989122
-
Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1α in advanced solid tumors
-
Kummar, S. et al. Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1α in advanced solid tumors. Clin. Cancer Res. 17, 5123-5131 (2011).
-
(2011)
Clin. Cancer Res.
, vol.17
, pp. 5123-5131
-
-
Kummar, S.1
-
78
-
-
4944229705
-
Schedule-dependent inhibition of hypoxia-inducible factor-1α protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts
-
Rapisarda, A. et al. Schedule-dependent inhibition of hypoxia-inducible factor-1α protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts. Cancer Res. 64, 6845-6848 (2004).
-
(2004)
Cancer Res.
, vol.64
, pp. 6845-6848
-
-
Rapisarda, A.1
-
79
-
-
67651166780
-
Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition
-
Rapisarda, A. et al. Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. Mol. Cancer Ther. 8, 1867-1877 (2009).
-
(2009)
Mol. Cancer Ther.
, vol.8
, pp. 1867-1877
-
-
Rapisarda, A.1
-
80
-
-
36048955738
-
Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: A pilot study
-
Chen, W. et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J. Clin. Oncol. 25, 4714-4721 (2007).
-
(2007)
J. Clin. Oncol.
, vol.25
, pp. 4714-4721
-
-
Chen, W.1
-
81
-
-
36049037819
-
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme
-
Vredenburgh, J. J. et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J. Clin. Oncol. 25, 4722-4729 (2007).
-
(2007)
J. Clin. Oncol.
, vol.25
, pp. 4722-4729
-
-
Vredenburgh, J.J.1
-
82
-
-
63149114714
-
Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia-inducible factor-1α axis
-
Pencreach, E. et al. Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia-inducible factor-1α axis. Clin. Cancer Res. 15, 1297-1307 (2009)
-
(2009)
Clin. Cancer Res.
, vol.15
, pp. 1297-1307
-
-
Pencreach, E.1
-
83
-
-
76049100577
-
HIF-1: Upstream and downstream of cancer metabolism
-
Semenza, G. L. HIF-1: upstream and downstream of cancer metabolism. Curr. Opin. Genet. Dev. 20, 51-56 (2010).
-
(2010)
Curr. Opin. Genet. Dev.
, vol.20
, pp. 51-56
-
-
Semenza, G.L.1
-
84
-
-
33644614520
-
HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia
-
Kim, J. W., Tchernyshyov, I., Semenza, G. L. & Dang, C. V. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 3, 177-185 (2006).
-
(2006)
Cell Metab.
, vol.3
, pp. 177-185
-
-
Kim, J.W.1
Tchernyshyov, I.2
Semenza, G.L.3
Dang, C.V.4
-
85
-
-
37549032776
-
The interplay between MYC and HIF in cancer
-
Dang, C. V., Kim, J. W., Gao, P. & Yustein, J. The interplay between MYC and HIF in cancer. Nat. Rev. Cancer 8, 51-56 (2008).
-
(2008)
Nat. Rev. Cancer
, vol.8
, pp. 51-56
-
-
Dang, C.V.1
Kim, J.W.2
Gao, P.3
Yustein, J.4
-
86
-
-
77951248644
-
Glucose deprivation-induced metabolic oxidative stress and cancer therapy
-
Simons, A. L., Mattson, D. M., Dornfeld, K. & Spitz, D. R. Glucose deprivation-induced metabolic oxidative stress and cancer therapy. J. Cancer Res. Ther. 5 (Suppl. 1), S2-S6 (2009).
-
(2009)
J. Cancer Res. Ther.
, vol.5
, Issue.SUPPL. 1
-
-
Simons, A.L.1
Mattson, D.M.2
Dornfeld, K.3
Spitz, D.R.4
-
87
-
-
52949145307
-
Glycolytic enzyme inhibitors in cancer treatment
-
Scatena, R., Bottoni, P., Pontoglio, A., Mastrototaro, L. & Giardina, B. Glycolytic enzyme inhibitors in cancer treatment. Expert. Opin. Investig. Drugs 17, 1533-1545 (2008).
-
(2008)
Expert. Opin. Investig. Drugs
, vol.17
, pp. 1533-1545
-
-
Scatena, R.1
Bottoni, P.2
Pontoglio, A.3
Mastrototaro, L.4
Giardina, B.5
-
88
-
-
79961215490
-
Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality
-
Chan, D. A. et al. Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality. Sci. Transl. Med. 3, 94ra70 (2011).
-
(2011)
Sci. Transl. Med.
, vol.3
-
-
Chan, D.A.1
-
89
-
-
78650722178
-
Anticancer drugs that target metabolism: Is dichloroacetate the new paradigm?
-
Papandreou, I., Goliasova, T. & Denko, N. C. Anticancer drugs that target metabolism: Is dichloroacetate the new paradigm? Int. J. Cancer 128, 1001-1008 (2011).
-
(2011)
Int. J. Cancer
, vol.128
, pp. 1001-1008
-
-
Papandreou, I.1
Goliasova, T.2
Denko, N.C.3
-
90
-
-
34249293335
-
Monocarboxylate transporter 4 regulates maturation and trafficking of CD147 to the plasma membrane in the metastatic breast cancer cell line MD-AMB-231
-
Gallagher, S. M., Castorino, J. J., Wang, D. & Philp, N. J. Monocarboxylate transporter 4 regulates maturation and trafficking of CD147 to the plasma membrane in the metastatic breast cancer cell line MD-AMB-231. Cancer Res. 67, 4182-4189 (2007).
-
(2007)
Cancer Res.
, vol.67
, pp. 4182-4189
-
-
Gallagher, S.M.1
Castorino, J.J.2
Wang, D.3
Philp, N.J.4
-
91
-
-
79955490807
-
Targeting tumor hypoxia: Suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors
-
Lou, Y. et al. Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res. 71, 3364-3376 (2011).
-
(2011)
Cancer Res.
, vol.71
, pp. 3364-3376
-
-
Lou, Y.1
-
92
-
-
84856152266
-
Targeting MET in cancer: Rationale and progress
-
Gherardi, E., Birchmeier, W., Birchmeier, C. & Vande Woude, G. Targeting MET in cancer: rationale and progress. Nat. Rev. Cancer 12, 89-103 (2012).
-
(2012)
Nat. Rev. Cancer
, vol.12
, pp. 89-103
-
-
Gherardi, E.1
Birchmeier, W.2
Birchmeier, C.3
Vande Woude, G.4
-
93
-
-
79960408937
-
VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer
-
You, W. K. et al. VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res. 71, 4758-4768 (2011).
-
(2011)
Cancer Res.
, vol.71
, pp. 4758-4768
-
-
You, W.K.1
-
94
-
-
77953090345
-
CXCL12 (SDF1)/CXCR4 pathway in cancer
-
Teicher, B. A. & Fricker, S. P. CXCL12 (SDF1)/CXCR4 pathway in cancer. Clin. Cancer Res. 16, 2927-2931 (2010).
-
(2010)
Clin. Cancer Res.
, vol.16
, pp. 2927-2931
-
-
Teicher, B.A.1
Fricker, S.P.2
-
95
-
-
79954606458
-
CXCL12 (SDF1α)-CXCR4/CXCR7 pathway inhibition: An emerging sensitizer for anticancer therapies?
-
Duda, D. G. et al. CXCL12 (SDF1α)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies? Clin. Cancer Res. 17, 2074-2080 (2011).
-
(2011)
Clin. Cancer Res.
, vol.17
, pp. 2074-2080
-
-
Duda, D.G.1
-
96
-
-
78449300594
-
CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression
-
Sun, X. et al. CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev. 29, 709-722 (2010).
-
(2010)
Cancer Metastasis Rev.
, vol.29
, pp. 709-722
-
-
Sun, X.1
-
97
-
-
77949697909
-
Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice
-
Kioi, M. et al. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J. Clin. Invest. 120, 694-705 (2010).
-
(2010)
J. Clin. Invest.
, vol.120
, pp. 694-705
-
-
Kioi, M.1
-
98
-
-
79958107497
-
Targeting SDF-1/CXCR4 to inhibit tumour vasculature for treatment of glioblastomas
-
Tseng, D., Vasquez-Medrano, D. A. & Brown, J. M. Targeting SDF-1/CXCR4 to inhibit tumour vasculature for treatment of glioblastomas. Br. J. Cancer 104, 1805-1809 (2011).
-
(2011)
Br. J. Cancer
, vol.104
, pp. 1805-1809
-
-
Tseng, D.1
Vasquez-Medrano, D.A.2
Brown, J.M.3
-
99
-
-
0036837864
-
Regulation of protein synthesis by hypoxia via activation of the endoplasmic reticulum kinase PERK and phosphorylation of the translation initiation factor eIF2α
-
Koumenis, C. et al. Regulation of protein synthesis by hypoxia via activation of the endoplasmic reticulum kinase PERK and phosphorylation of the translation initiation factor eIF2α. Mol. Cell Biol. 22, 7405-7416 (2002).
-
(2002)
Mol. Cell Biol.
, vol.22
, pp. 7405-7416
-
-
Koumenis, C.1
-
100
-
-
4344660747
-
XBP1 is essential for survival under hypoxic conditions and is required for tumor growth
-
Romero-Ramirez, L. et al. XBP1 is essential for survival under hypoxic conditions and is required for tumor growth. Cancer Res. 64, 5943-5947 (2004).
-
(2004)
Cancer Res.
, vol.64
, pp. 5943-5947
-
-
Romero-Ramirez, L.1
-
101
-
-
36348936212
-
Oxygen-dependent ATF-4 stability is mediated by the PHD3 oxygen sensor
-
Köditz, J. et al. Oxygen-dependent ATF-4 stability is mediated by the PHD3 oxygen sensor. Blood 110, 3610-3617 (2007).
-
(2007)
Blood
, vol.110
, pp. 3610-3617
-
-
Köditz, J.1
-
102
-
-
79251589342
-
Identification of an Ire1α endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma
-
Papandreou, I. et al. Identification of an Ire1α endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma. Blood 117, 1311-1314 (2011).
-
(2011)
Blood
, vol.117
, pp. 1311-1314
-
-
Papandreou, I.1
-
103
-
-
75149165640
-
Imaging the unfolded protein response in primary tumors reveals microenvironments with metabolic variations that predict tumor growth
-
Spiotto, M. T. et al. Imaging the unfolded protein response in primary tumors reveals microenvironments with metabolic variations that predict tumor growth. Cancer Res. 70, 78-88 (2010).
-
(2010)
Cancer Res.
, vol.70
, pp. 78-88
-
-
Spiotto, M.T.1
-
104
-
-
56449087512
-
Preferential cytotoxicity of bortezomib toward hypoxic tumor cells via overactivation of endoplasmic reticulum stress pathways
-
Fels, D. R. et al. Preferential cytotoxicity of bortezomib toward hypoxic tumor cells via overactivation of endoplasmic reticulum stress pathways. Cancer Res. 68, 9323-9330 (2008).
-
(2008)
Cancer Res.
, vol.68
, pp. 9323-9330
-
-
Fels, D.R.1
-
105
-
-
77955467319
-
Regulation of autophagy by ATF4 in response to severe hypoxia
-
Rzymski, T. et al. Regulation of autophagy by ATF4 in response to severe hypoxia. Oncogene 29, 4424-4435 (2010).
-
(2010)
Oncogene
, vol.29
, pp. 4424-4435
-
-
Rzymski, T.1
-
106
-
-
36749001007
-
Oxygen sensing and the DNA-damage response
-
Hammond, E. M., Kaufmann, M. R. & Giaccia, A. J. Oxygen sensing and the DNA-damage response. Curr. Opin. Cell Biol. 19, 680-684 (2007).
-
(2007)
Curr. Opin. Cell Biol.
, vol.19
, pp. 680-684
-
-
Hammond, E.M.1
Kaufmann, M.R.2
Giaccia, A.J.3
-
107
-
-
39749166975
-
DNA repair pathways as targets for cancer therapy
-
Helleday, T., Petermann, E., Lundin, C., Hodgson, B. & Sharma, R. A. DNA repair pathways as targets for cancer therapy. Nat. Rev. Cancer 8, 193-204 (2008).
-
(2008)
Nat. Rev. Cancer
, vol.8
, pp. 193-204
-
-
Helleday, T.1
Petermann, E.2
Lundin, C.3
Hodgson, B.4
Sharma, R.A.5
-
108
-
-
4644318239
-
Inhibition of ATR leads to increased sensitivity to hypoxia/reoxygenation
-
Hammond, E. M., Dorie, M. J. & Giaccia, A. J. Inhibition of ATR leads to increased sensitivity to hypoxia/reoxygenation. Cancer Res. 64, 6556-6562 (2004).
-
(2004)
Cancer Res.
, vol.64
, pp. 6556-6562
-
-
Hammond, E.M.1
Dorie, M.J.2
Giaccia, A.J.3
-
109
-
-
74249092481
-
Biomarkers of angiogenesis and their role in the development of VEGF inhibitors
-
Murukesh, N., Dive, C. & Jayson, G. C. Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br. J. Cancer 102, 8-18 (2010).
-
(2010)
Br. J. Cancer
, vol.102
, pp. 8-18
-
-
Murukesh, N.1
Dive, C.2
Jayson, G.C.3
-
110
-
-
79851501698
-
Molecular imaging of hypoxia
-
Chitneni, S. K., Palmer, G. M., Zalutsky, M. R. & Dewhirst, M. W. Molecular imaging of hypoxia. J. Nucl. Med. 52, 165-168 (2011).
-
(2011)
J. Nucl. Med.
, vol.52
, pp. 165-168
-
-
Chitneni, S.K.1
Palmer, G.M.2
Zalutsky, M.R.3
Dewhirst, M.W.4
-
111
-
-
70350545808
-
Molecular imaging of hypoxia with radiolabelled agents
-
Mees, G., Dierckx, R., Vangestel, C. & Van de Wiele, C. Molecular imaging of hypoxia with radiolabelled agents. Eur. J. Nucl. Med. Mol. Imaging 36, 1674-1686 (2009).
-
(2009)
Eur. J. Nucl. Med. Mol. Imaging
, vol.36
, pp. 1674-1686
-
-
Mees, G.1
Dierckx, R.2
Vangestel, C.3
Van De Wiele, C.4
-
112
-
-
84857915848
-
Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies
-
O'Connor, J. P., Jackson, A., Parker, G. J., Roberts, C. & Jayson, G. C. Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies. Nat. Rev. Clin. Onc. 9, 1676-177 (2012).
-
(2012)
Nat. Rev. Clin. Onc.
, vol.9
, pp. 1676-2177
-
-
O'Connor, J.P.1
Jackson, A.2
Parker, G.J.3
Roberts, C.4
Jayson, G.C.5
-
113
-
-
59949102930
-
A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer
-
Hecht, J. R. et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J. Clin. Oncol. 27, 672-680 (2009).
-
(2009)
J. Clin. Oncol.
, vol.27
, pp. 672-680
-
-
Hecht, J.R.1
-
114
-
-
59749091477
-
Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer
-
Tol, J. et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N. Engl. J. Med. 360, 563-572 (2009).
-
(2009)
N. Engl. J. Med.
, vol.360
, pp. 563-572
-
-
Tol, J.1
-
115
-
-
79551521053
-
Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: Results of NSABP protocol C08 J
-
Allegra, C. J. et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C08 J. Clin. Oncol. 29, 11-16 (2011).
-
(2011)
Clin. Oncol.
, vol.29
, pp. 11-16
-
-
Allegra, C.J.1
-
116
-
-
37549040613
-
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
-
Miller, K. et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 357, 2666-2676 (2007).
-
(2007)
N. Engl. J. Med.
, vol.357
, pp. 2666-2676
-
-
Miller, K.1
-
117
-
-
59849105332
-
Avastin-Tarceva combination fails in lung cancer
-
Jones, D. Avastin-Tarceva combination fails in lung cancer. Nat. Biotechnol. 27, 108-109 (2009).
-
(2009)
Nat. Biotechnol.
, vol.27
, pp. 108-109
-
-
Jones, D.1
-
118
-
-
80053573446
-
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: A randomized, double-blind, placebo-controlled phase III study
-
Ohtsu, A. et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J. Clin. Oncol. 29, 3968-3976 (2011).
-
(2011)
J. Clin. Oncol.
, vol.29
, pp. 3968-3976
-
-
Ohtsu, A.1
-
119
-
-
77955887676
-
Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: Phase III trial of the Cancer and Leukemia Group B (CALGB 80303)
-
Kindler, H. L. et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J. Clin. Oncol. 28, 3617-3622 (2010).
-
(2010)
J. Clin. Oncol.
, vol.28
, pp. 3617-3622
-
-
Kindler, H.L.1
-
120
-
-
65549150854
-
Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer
-
Van Cutsem, E. et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J. Clin. Oncol. 27, 2231-2237 (2009).
-
(2009)
J. Clin. Oncol.
, vol.27
, pp. 2231-2237
-
-
Van Cutsem, E.1
-
121
-
-
77955714649
-
A randomized double-blind placebo-controlled phase III trial comparing docetaxel prednisone and placebo with docetaxel prednisone and bevacizumab in men with metastatic castration-resistant prostate cancer (MCRPC): Survival results of CALGB 90401 [abstract]
-
LBA511
-
Kelly, W. K. et al. A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (MCRPC): survival results of CALGB 90401 [abstract]. J. Clin. Oncol. 28 (Suppl.) 18s LBA511 (2010).
-
(2010)
J. Clin. Oncol.
, vol.28
, Issue.SUPPL.
, pp. 18
-
-
Kelly, W.K.1
-
122
-
-
78651408563
-
Glioblastoma recurrence after cediranib therapy in patients: Lack of "rebound" revascularization as mode of escape
-
di Tomaso, E. et al. Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape. Cancer Res. 71, 19-28 (2011).
-
(2011)
Cancer Res.
, vol.71
, pp. 19-28
-
-
Di Tomaso, E.1
-
123
-
-
77951296573
-
Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer
-
Barrios, C. H. et al. Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res. Treat. 121, 121-131 (2010).
-
(2010)
Breast Cancer Res. Treat.
, vol.121
, pp. 121-131
-
-
Barrios, C.H.1
-
124
-
-
77951639655
-
Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer
-
Scagliotti, G. et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J. Clin. Oncol. 28, 1835-1842 (2010).
-
(2010)
J. Clin. Oncol.
, vol.28
, pp. 1835-1842
-
-
Scagliotti, G.1
-
125
-
-
79952748468
-
Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer
-
Natale, R. B. et al. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J. Clin. Oncol. 29, 1059-1066 (2011).
-
(2011)
J. Clin. Oncol.
, vol.29
, pp. 1059-1066
-
-
Natale, R.B.1
-
126
-
-
79952742483
-
Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: A randomized, double-blind phase III trial
-
de Boer, R. H. et al. Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. J. Clin. Oncol. 29, 1067-1074 (2011).
-
(2011)
J. Clin. Oncol.
, vol.29
, pp. 1067-1074
-
-
De Boer, R.H.1
-
127
-
-
75449088610
-
FDA drug approval summary: Bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme
-
Cohen, M. H., Shen, Y. L., Keegan, P. & Pazdur, R. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist 14, 1131-1138 (2009).
-
(2009)
Oncologist
, vol.14
, pp. 1131-1138
-
-
Cohen, M.H.1
Shen, Y.L.2
Keegan, P.3
Pazdur, R.4
-
128
-
-
2542561964
-
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
-
Hurwitz, H. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335-2342 (2004).
-
(2004)
N. Engl. J. Med.
, vol.350
, pp. 2335-2342
-
-
Hurwitz, H.1
-
129
-
-
42949149159
-
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study
-
Saltz, L. B. et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J. Clin. Oncol. 26, 2013-2019 (2008).
-
(2008)
J. Clin. Oncol.
, vol.26
, pp. 2013-2019
-
-
Saltz, L.B.1
-
130
-
-
34248173883
-
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200
-
Giantonio, B. J. et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol. 25, 1539-1544 (2007).
-
(2007)
J. Clin. Oncol.
, vol.25
, pp. 1539-1544
-
-
Giantonio, B.J.1
-
131
-
-
77954700380
-
Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer
-
Miles, D. W. et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J. Clin. Oncol. 28, 3239-3247 (2010).
-
(2010)
J. Clin. Oncol.
, vol.28
, pp. 3239-3247
-
-
Miles, D.W.1
-
132
-
-
79953874259
-
RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer
-
Robert, N. J. et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J. Clin. Oncol. 29, 1252-1260 (2011).
-
(2011)
J. Clin. Oncol.
, vol.29
, pp. 1252-1260
-
-
Robert, N.J.1
-
133
-
-
81155123190
-
RIBBON-2: A randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer
-
Brufsky, A. M. et al., RIBBON-2: A randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J. Clin. Oncol. 29, 4286-4293 (2011).
-
(2011)
J. Clin. Oncol.
, vol.29
, pp. 4286-4293
-
-
Brufsky, A.M.1
-
134
-
-
33845490014
-
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
-
Sandler, A. et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355, 2542-2550 (2006).
-
(2006)
N. Engl. J. Med.
, vol.355
, pp. 2542-2550
-
-
Sandler, A.1
-
135
-
-
77951473661
-
Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: Results from a randomised phase III trial (AVAiL)
-
Reck, M. et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann. Oncol. 21, 1804-1809 (2010).
-
(2010)
Ann. Oncol.
, vol.21
, pp. 1804-1809
-
-
Reck, M.1
-
136
-
-
77952300540
-
Phase III trial of bevacizumab plus interferon α-2α in patients with metastatic renal cell carcinoma (AVOREN): Final analysis of overall survival
-
Escudier, B. et al. Phase III trial of bevacizumab plus interferon α-2α in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J. Clin. Oncol. 28, 2144-2150 (2010).
-
(2010)
J. Clin. Oncol.
, vol.28
, pp. 2144-2150
-
-
Escudier, B.1
-
137
-
-
77952318310
-
Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: Final results of CALGB 90206
-
Rini, B. I. et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J. Clin. Oncol. 28, 2137-2143 (2010).
-
(2010)
J. Clin. Oncol.
, vol.28
, pp. 2137-2143
-
-
Rini, B.I.1
-
138
-
-
79955101754
-
Potential of CXCR4 antagonists for the treatment of metastatic lung cancer
-
Burger, J. A., Stewart, D. J., Wald, O. & Peled, A. Potential of CXCR4 antagonists for the treatment of metastatic lung cancer. Expert. Rev. Anticancer Ther. 11, 621-630 (2011).
-
(2011)
Expert. Rev. Anticancer Ther.
, vol.11
, pp. 621-630
-
-
Burger, J.A.1
Stewart, D.J.2
Wald, O.3
Peled, A.4
-
139
-
-
68949145218
-
Overall survival and updated results for sunitinib compared with interferon α in patients with metastatic renal cell carcinoma
-
Motzer, R. J. et al. Overall survival and updated results for sunitinib compared with interferon α in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27, 3584-3590 (2009)
-
(2009)
J. Clin. Oncol.
, vol.27
, pp. 3584-3590
-
-
Motzer, R.J.1
-
140
-
-
33947423448
-
Approval summary: Sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma
-
Goodman, V. L. et al. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin. Cancer Res. 13, 1367-1373 (2007).
-
(2007)
Clin. Cancer Res.
, vol.13
, pp. 1367-1373
-
-
Goodman, V.L.1
-
141
-
-
79851482955
-
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors
-
Raymond, E. et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N. Engl. J. Med. 364, 501-513 (2011).
-
(2011)
N. Engl. J. Med.
, vol.364
, pp. 501-513
-
-
Raymond, E.1
-
142
-
-
70249097380
-
Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial
-
Escudier, B. et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J. Clin. Oncol. 27, 3312-3318 (2009).
-
(2009)
J. Clin. Oncol.
, vol.27
, pp. 3312-3318
-
-
Escudier, B.1
-
143
-
-
47949116252
-
Sorafenib in advanced hepatocellular carcinoma
-
Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378-390 (2008).
-
(2008)
N. Engl. J. Med.
, vol.359
, pp. 378-390
-
-
Llovet, J.M.1
-
144
-
-
77949890945
-
Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial
-
Sternberg, C. N. et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J. Clin. Oncol. 28, 1061-1068 (2010).
-
(2010)
J. Clin. Oncol.
, vol.28
, pp. 1061-1068
-
-
Sternberg, C.N.1
-
145
-
-
77954035012
-
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): A double-blind, randomised, phase 3 trial
-
Herbst, R. S. et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol. 11, 619-626 (2010).
-
(2010)
Lancet Oncol.
, vol.11
, pp. 619-626
-
-
Herbst, R.S.1
-
146
-
-
84055190019
-
Antiangiogenic and radiation therapy: Early effects on in vivo computed tomography perfusion parameters in human colon cancer xenografts in mice
-
Ren, Y. et al. Antiangiogenic and radiation therapy: early effects on in vivo computed tomography perfusion parameters in human colon cancer xenografts in mice. Invest. Radiol. 47, 25-32 (2012).
-
(2012)
Invest. Radiol.
, vol.47
, pp. 25-32
-
-
Ren, Y.1
-
147
-
-
78650401560
-
HIF-2α enhances β-catenin/TCF-driven transcription by interacting with β-catenin
-
Choi, H., Chun, Y. S., Kim, T. Y. & Park, J. W. HIF-2α enhances β-catenin/TCF-driven transcription by interacting with β-catenin. Cancer Res. 70, 10101-10111 (2010).
-
(2010)
Cancer Res.
, vol.70
, pp. 10101-10111
-
-
Choi, H.1
Chun, Y.S.2
Kim, T.Y.3
Park, J.W.4
-
148
-
-
75849160216
-
Human cancers converge at the HIF-2α oncogenic axis
-
Franovic, A., Holterman, C. E., Payette, J. & Lee, S. Human cancers converge at the HIF-2α oncogenic axis. Proc. Natl Acad. Sci. USA 106, 21306-21311 (2009).
-
(2009)
Proc. Natl Acad. Sci. USA
, vol.106
, pp. 21306-21311
-
-
Franovic, A.1
Holterman, C.E.2
Payette, J.3
Lee, S.4
-
149
-
-
79957894276
-
Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases
-
Carmeliet, P. & Jain, R. K. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat. Rev. Drug Discov. 10, 417-427 (2011).
-
(2011)
Nat. Rev. Drug Discov.
, vol.10
, pp. 417-427
-
-
Carmeliet, P.1
Jain, R.K.2
-
150
-
-
79960096827
-
Normalization of the vasculature for treatment of cancer and other diseases
-
Goel, S. et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol. Rev. 91, 1071-1121 (2011).
-
(2011)
Physiol. Rev.
, vol.91
, pp. 1071-1121
-
-
Goel, S.1
-
151
-
-
79960924361
-
Vascular normalization: A real benefit?
-
Ribatti, D. Vascular normalization: a real benefit? Cancer Chemother. Pharmacol. 68, 275-278 (2011).
-
(2011)
Cancer Chemother. Pharmacol.
, vol.68
, pp. 275-278
-
-
Ribatti, D.1
|